| Project/Area Number |
10557053
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | UNIVERSITY OF TOKYO |
|---|
Principal Investigator |
KOIKE Kazuhiko UNIVERSITY OF TOKYO, DPT OF MEDICINE, ASSOCIATE PROFESSOR, 医学部・附属病院, 助教授 (80240703)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHINTANI Yoshizumi UNIVERSITY OF TOKYO, DPT OF MEDICINE, MEDICAL STUFF, 医学部・附属病院, 医員
MORIYA Kyoji UNIVERSITY OF TOKYO, DPT OF MEDICINE, ASSISTANT PROFESSOR, 医学部・附属病院, 助手
MATSUURA Yoshiharu NATL. INST. OF INFECT. DIS., SECTION CHIEF, 室長
ISHIBASHI Kotaro DAIICHI PHARMACEUTICALS, CHIEF SCIENTIST, 主任研究員(研究職)
松浦 義治 国立感染症研究所, 室長
四柳 宏 東京大学, 医学部附属病院, 医員
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥13,600,000 (Direct Cost: ¥13,600,000)
Fiscal Year 1999: ¥4,500,000 (Direct Cost: ¥4,500,000)
Fiscal Year 1998: ¥9,100,000 (Direct Cost: ¥9,100,000)
|
|---|
| Keywords | hepatitis C virus / transgenic mice / core protein / hepatocellular carcinoma / hepatitis / steatosis / アデノウイルス / C型肝炎 / エンベロープ蛋白 |
|---|
| Research Abstract |
Hepatitis C virus (HCV) and hepatitis B virus (HBV) are the major causative agents responsible for the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Currently, interferons are mainly used for the treatment of chronic hepatitis which is induced by these two agents. However, its efficacy is limited and development of new anti-viral agents is indispensable. We attempted to make recombinant baculoviruses carrying the interferon-γ for the future application to human chronic hepatitis treatment. Interferon-γ gene was efficiently expressed in HepG2 cells using the recombinant baculovirus. In 2.2.l5 cell lines which produces HBV particles, replication of HBV was significantly inhibited by infection with recombinant baculovirus. Inoculation of mice with baculovirus has not led to the production of genes so far, and further trials are now underway. This recombinant baculovirus system which produces interferon-γ is a promising device for future treatment of hardly curable chronic hepatitis.
|
